Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Jun 25, 2015; 6(6): 840-849
Published online Jun 25, 2015. doi: 10.4239/wjd.v6.i6.840
Published online Jun 25, 2015. doi: 10.4239/wjd.v6.i6.840
Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors
Yuya Nakamura, Masatomo Mihara, Tatsuo Shimizu, Michiyasu Inoue, Yoshikazu Goto, Hiromichi Gotoh, Saiyu Soka Hospital, Kitaya, Soka-city Saitama-ken 340-0046, Japan
Hitomi Hasegawa, Mayumi Tsuji, Yuko Udaka, Katsuji Oguchi, Department of Pharmacology, School of Medicine, Showa University, Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan
Masahiro Inagaki, Department of Chemistry, College of Arts and Sciences, Showa University, Kamiyoshida, Fujiyoshida-city, Yamanashi-ken 403-0005, Japan
Author contributions: Nakamura Y devised the study concept and design; Nakamura Y searched the literature; Nakamura Y, Shimizu T, Goto Y and Gotoh H analyzed the literature; Nakamura Y, Hasegawa H, Udaka Y and Mihara M interpreted the literature; Nakamura Y drafted the article; Nakamura Y, Tsuji M and Inagaki M revised the article for important intellectual content; Oguchi K gave final approval for the article.
Conflict-of-interest: There are no conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Yuya Nakamura, MD, Saiyu Soka Hospital, 1-21-37, Kitaya, Soka-city Saitama-ken 340-0046, Japan. y.nakamura@med.showa-u.ac.jp
Telephone: +81-4-89446111 Fax: +81-4-89448080
Received: August 22, 2014
Peer-review started: August 23, 2014
First decision: September 28, 2014
Revised: March 16, 2015
Accepted: April 1, 2015
Article in press: April 7, 2015
Published online: June 25, 2015
Processing time: 302 Days and 5.8 Hours
Peer-review started: August 23, 2014
First decision: September 28, 2014
Revised: March 16, 2015
Accepted: April 1, 2015
Article in press: April 7, 2015
Published online: June 25, 2015
Processing time: 302 Days and 5.8 Hours
Core Tip
Core tip: Until now, the effectiveness of dipeptidase-4 (DPP-4) inhibitors on diabetic hemodialysis (HD) patients has not been reviewed. All 7 DPP-4 inhibitors are available for HD patients; administration is once daily with dose adjustments. The effectiveness of DPP-4 inhibitor treatment in HD patients is high, and adverse events do not increase as a result. DPP-4 inhibitors may prevent inflammation and atherosclerosis, which are principal prognostic factors for HD patients. In summary, DPP-4 inhibitors are key drugs in new treatment strategies for HD patients with diabetes and limited choices for its treatment.